Interim results for the six months ended june 30, 2024

September 26, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) interim results for the six months ended june 30, 2024 biodexa pharmaceuticals plc (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended june 30, 2024 which will also be made available on the company's website at www.biodexapharma.com operational highlights the company announced the following in the six months ended june 30, 2024: exclusive worldwide licensing of erapa™, a phase 3 ready asset with a lead indication of familial adenomatous polyposis (“fap”) together with access to a $17 million grant. six month data of erapa in fap showing an 83% non-progression rate and a statistically significant reduction on overall polyp burden, announced at the digestive disease week scientific meeting in washington d.c.
BDRX Ratings Summary
BDRX Quant Ranking